IKT

Inhibikase Therapeutics Inc

• TipRanks·2d ago

  Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway

• TipRanks·3d ago

  Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target

• TipRanks·3d ago

  Inhibikase Begins Pivotal Phase 3 Trial in PAH

• TipRanks·3d ago

  Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study

• Reuters·3d ago

  Inhibikase enrolls first patient in Phase 3 IMPROVE-PAH trial for IKT-001

• Benzinga·3d ago

  Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatment Of Pulmonary Arterial Hypertension

• Reuters·3d ago

  INHIBIKASE THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN IMPROVE-PAH GLOBAL PHASE 3 STUDY OF IKT-001 IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

• TipRanks·3d ago

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• Reuters·04/03 18:01

  Inhibikase grants 685,718 inducement stock options to five new hires at $1.68/share

• Reuters·04/03 18:01

  INHIBIKASE THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• TipRanks·04/02 12:30

  Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD) and Apogee Therapeutics (APGE)

• TipRanks·03/30 10:37

  Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright

• TipRanks·03/27 13:10

  Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Rockwell Med (RMTI) and Inhibikase Therapeutics (IKT)

• Seeking Alpha·03/26 20:36

  Inhibikase Therapeutics GAAP EPS of -$0.49

• Reuters·03/26 20:05

  Inhibikase Therapeutics FY2025 net loss widens 75.39% to $48 million; R&D expenses climb 73.13% to $30 million